己糖激酶Ⅱ与肿瘤增殖及靶向治疗

doi:10.3760/cma.j.issn.1673422X.2017.03.014

摘要/Abstract

摘要： 肿瘤细胞所需能量主要来自有氧糖酵解途径，即Warburg效应，该生化过程同时为肿瘤细胞提供生长所需的大量前体物质。已糖激酶Ⅱ（HKⅡ）为糖酵解的限速酶，在肿瘤组织中高表达，与肿瘤的能量代谢密切相关。近年来研究表明肿瘤细胞中的HKⅡ不仅介导Warburg效应，还能抑制肿瘤细胞凋亡、调节自噬而发挥促进肿瘤增殖的作用。已在多种肿瘤细胞中证实，阻断HKⅡ基因表达及应用HKⅡ的小分子抑制剂均可起到杀伤肿瘤的作用，以HKⅡ为靶点的抑制剂有可能成为新一代靶向药物。

关键词: 己糖激酶, 肿瘤, 细胞增殖, 靶向治疗

Abstract: The energy for tumor cells mainly derives from the aerobic glycolysis, that is, the Warburg effect, which also provides a large amount of precursor substances for the growth of tumor cells. HexokinaseⅡ (HKⅡ), highly expressed in tumor tissue, is the ratelimiting enzyme of glycolysis and closely related to the energy metabolism of tumor. Recent studies have showed that HKⅡ not only mediates Warburg effect, but also promotes tumor proliferation by inhibiting tumor cell apoptosis and regulating autophagy. It has been confirmed that blocking HKⅡ gene expression and inhibiting HKⅡ with small molecule inhibitor can kill tumor cells in many kinds of cancer. Agent targeting HKⅡ may become a new generation of targeted drugs.

Key words: Hexokinase, Neoplasms, Cell proliferation; Target therapy

王豪华,陈秀星,郭桂芳. 己糖激酶Ⅱ与肿瘤增殖及靶向治疗[J]. 国际肿瘤学杂志, 2017, 44(3): 213-216.

Wang Haohua, Chen Xiuxing, Guo Guifang. exokinaseⅡ role in tumor growth and targeting therapyW[J]. Journal of International Oncology, 2017, 44(3): 213-216.

参考文献

［1］ Masoud GN, Li W. HIF1alpha pathway: role, regulation and intervention for cancer therapy［J］. Acta pharmaceutica Sinica B, 2015, 5 (5): 378-389. DOI: 10.1016/j.apsb.2015.05.007. ［2］ Gregersen LH, Jacobsen A, Frankel LB, et al. MicroRNA143 downregulates Hexokinase 2 in colon cancer cells［J］. BMC Cancer, 2012, 12: 232. DOI: 10.1186/1471240712232. ［3］ Yoshino H, Enokida H, Itesako T, et al. Tumorsuppressive microRNA 143/145 cluster targets hexokinase2 in renal cell carcinoma［J］. Cancer Sci, 2013, 104(12): 1567-1574. DOI: 10.1111/cas.12280. ［4］ Jiang S, Zhang LF, Zhang HW, et al. A novel miR155/miR143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells［J］. EMBO J, 2012, 31(8): 1985-1998. DOI: 10.1038/emboj.2012.45. ［5］ Zhang LF, Lou JT, Lu MH, et al. Suppression of miR199a maturation by HuR is crucial for hypoxiainduced glycolytic Switch in hepatocellular carcinoma［J］. EMBO J, 2015, 34(21): 2671-2685. DOI: 10.15252/embj.201591803. ［6］ Li LQ, Yang Y, Chen H, et al. MicroRNA181b inhibits glycolysis in gastric cancer cells via targeting hexokinase 2 gene［J］. Cancer Biomark, 2016, 17(1): 75-81. DOI: 10.3233/CBM160619. ［7］ Wang Y, Yun Y, Wu B, et al. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription［J］. Oncotarget, 2016, In press. DOI: 10.18632/oncotarget.10103. ［8］ Roberts DJ, Miyamoto S. Hexokinase Ⅱ integrates energy metabolism and cellular protection: akting on mitochondria and TORCing to autophagy［J ］. Cell Death Differ, 2015, 22(2): 248-257. DOI: 10.1038/cdd.2014.173. ［9］ Pantic B, Trevisan E, Citta A, et al. Myotonic dystrophy protein kinase (DMPK) prevents ROSinduced cell death by assembling a hexokinase ⅡSrc complex on the mitochondrial surface［J］. Cell Death Dis, 2013, 4: e858. DOI: 10.1038/cddis.2013.385. ［10］ Roberts DJ, TanSah VP, Ding EY, et al. HexokinaseⅡ positively regulates glucose starvationinduced autophagy through TORC1 inhibition［J ］. Mol Cell, 2014, 53(4): 521-533. DOI: 10.1016/j.molcel.2013.12.019. ［11］ Tan VP, Miyamoto S. HK2/hexokinaseⅡ integrates glycolysis and autophagy to confer cellular protection［J］. Autophagy, 2015, 11(6): 963- 964. DOI: 10.1080/15548627.2015.1042195. ［12］ Kim JE, Ahn BC, Hwang MH, et al. Combined RNA interference of hexokinase Ⅱ and (131)Isodium iodide symporter gene therapy for anaplastic thyroid carcinoma［J］ . J Nucl Med, 2011, 52(11): 1756-1763. DOI: 10.2967/jnumed.111.090266. ［13］ Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme［J］. J Exp Med, 2011, 208(2): 313-326. DOI: 10.1084/jem.20101470. ［14］ Patra KC, Wang Q, Bhaskar PT, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer［J］. Cancer Cell, 2013, 24(2): 213-228. DOI: 10.1016/j.ccr.2013.06.014. ［15］ Gong L, Wei Y, Yu X, et al. 3Bromopyruvic acid, a hexokinase Ⅱ inhibitor, is an effective antitumor agent on the hepatoma cells: in vitro and in vivo findings［J］. Anticancer Agents Med Chem, 2014, 14(5): 771-776. ［16］ Buijs M, Wijlemans JW, Kwak BK, et al. Antiglycolytic therapy combined with an imageguided minimally invasive delivery strategy for the treatment of breast cancer［J］. J Vasc Interv Radiol, 2013, 24(5): 737-743. DOI: 10.1016/j.jvir.2013.01.013. ［17］ Wicks RT, Azadi J, Mangraviti A, et al. Local delivery of cancercell glycolytic inhibitors in highgrade glioma［J］. Neuro Oncol, 2015, 17(1): 70-80. DOI: 10.1093/neuonc/nou143. ［18］ Krasnov GS, Dmitriev AA, Lakunina VA, et al. Targeting VDACbound hexokinase Ⅱ: a promising approach for concomitant anticancer therapy［J ］. Expert Opin Ther Targets, 2013, 17(10): 1221-1233. DOI: 10.1517/14728222.2013.833607. ［19］ Wintzell M, Lfstedt L, Johansson J, et al. Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3bromopyruvate［J］. Cancer Biol Ther, 2012, 13(14): 1454-1462. DOI: 10.4161/cbt.22007. ［20］ Bean JF, Qiu YY, Yu S, et al. Glycolysis inhibition and its effect in doxorubicin resistance in neuroblastoma［J］. J Pediatr Surg, 2014, 49 (6): 981-984; discussion 984. DOI: 10.1016/j.jpedsurg.2014.01.037. ［21］ GarbutcheonSingh KB, Harper BW, Myers S, et al. Combination studies of Platinum(Ⅱ)based metallointercalators with buthionineS, R sulfoximine, 3bromopyruvate, cisplatin or carboplatin［J］. Metallomics, 2014, 6(1): 126-131. DOI: 10.1039/c3mt00191a. ［22］ Marrache S, Dhar S. The energy blocker inside the power house: mitochondria targeted delivery of 3bromopyruvate［J］. Chem Sci, 2015, 6 (3): 1832-1845. ［23］ Zhang MX, Hua YJ, Wang HY, et al. Longterm prognostic implications and therapeutic target role of hexokinase Ⅱ in patients with nasopharyngeal carcinoma［J］. Oncotarget, 2016, 7(16): 21287-21297. DOI: 10.18632/oncotarget.7116. ［24］ Kennedy CR, Tilkens SB, Guan H, et al. Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions ［J］. Cancer Lett, 2013, 336(2): 299-306. DOI: 10.1016/j.canlet.2013.03.020. ［25］ Cheong JH, Park ES, Liang J, et al. Dual inhibition of tumor energy pathway by 2deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models［J］. Mol Cancer Ther, 2011, 10(12): 2350-2362. DOI: 10.1158/15357163.MCT110497.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.